Literature DB >> 22283674

Microalbuminuria and left ventricular mass in overweight and obese hypertensive patients: role of the metabolic syndrome.

Federico Guerra1, Lucia Mancinelli, Alessia Buglioni, Valentina Pierini, Alessandro Rappelli, Paolo Dessì-Fulgheri, Riccardo Sarzani.   

Abstract

BACKGROUND: Left ventricular hypertrophy (LVH) and microalbuminuria are common in hypertensive patients and are often associated with metabolic syndrome (MetS). However, it is not clear whether MetS could modify the association between cardiac and renal damage.
OBJECTIVE: The aim of this study was to assess if the relationship of albumin/creatinine ratio (ACR) and left ventricular mass (LVM) could be independent from MetS in hypertensive overweight/obese patients.
METHODS: 180 essential hypertensive and overweight/obese (body mass index [BMI] ≥25 kg/m(2)) patients referred to our Hypertension Centre from January 2006 to April 2009 because of blood pressure (BP) control-related problems were studied. Exclusion criteria were scarce adherence to antihypertensive drug therapy as investigated by the Morisky Medical Adherence Scale (MMAS), heart failure (New York Heart Association III or IV or left ventricular ejection fraction [LVEF] <50%), liver failure, cancer or other systemic severe diseases. MetS was defined according to the National Cholesterol Education Program (USA) Adult Treatment Panel III classification as modified by the American Heart Association. ACR was obtained from first morning urine specimens. Left ventricular dimensions, mass and ejection fraction, were measured by echocardiography following the American Society of Echocardiography recommendations.
RESULTS: Patients with microalbuminuria had a 6-fold higher risk for LVH/h(2.7) and 2-fold higher risk for LVH/body surface area (BSA). Univariate linear regression analysis showed a positive relationship between ACR and LVM, expressed both as LVM/h(2.7) or LVM/BSA, as well as a direct correlation between logACR and interventricular diameters and ejection fraction. Regression models including logACR, estimated glomerular filtration rate, BMI, age, hypertension duration, smoking and MetS (as a single variable as well as each single component), showed that only logACR, BMI, hypertension duration and systolic blood pressure (SBP) were independently associated with LVM/h(2.7).
CONCLUSION: Along with BP and BMI, albuminuria measured in a morning urine sample as ACR is a valuable low-cost index of cardiac organ damage and increased cardiovascular risk in hypertensive patients independently by MetS. On the other hand, MetS is not an independent risk factor for cardiac damage because it does not seem to add anything more than the sum of each of its components (especially SBP and adiposity indexed by BMI) to the relationship between cardiac and renal subclinical organ damage.
© 2011 Adis Data Information BV. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22283674     DOI: 10.2165/11593650-000000000-00000

Source DB:  PubMed          Journal:  High Blood Press Cardiovasc Prev        ISSN: 1120-9879


  30 in total

1.  Prediction of coronary heart disease using risk factor categories.

Authors:  P W Wilson; R B D'Agostino; D Levy; A M Belanger; H Silbershatz; W B Kannel
Journal:  Circulation       Date:  1998-05-12       Impact factor: 29.690

2.  Cardiovascular morbidity and mortality associated with the metabolic syndrome.

Authors:  B Isomaa; P Almgren; T Tuomi; B Forsén; K Lahti; M Nissén; M R Taskinen; L Groop
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

Review 3.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Richard Kahn; John Buse; Ele Ferrannini; Michael Stern
Journal:  Diabetes Care       Date:  2005-09       Impact factor: 19.112

4.  Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk.

Authors:  G de Simone; R B Devereux; S R Daniels; M J Koren; R A Meyer; J H Laragh
Journal:  J Am Coll Cardiol       Date:  1995-04       Impact factor: 24.094

5.  Novel use of Kaplan-Meier methods to explain age and gender differences in hypertension control rates.

Authors:  Kent R Bailey; Brandon R Grossardt; John W Graves
Journal:  Hypertension       Date:  2008-03-10       Impact factor: 10.190

Review 6.  Left ventricular hypertrophy and clinical outcomes in hypertensive patients.

Authors:  Luis M Ruilope; Roland E Schmieder
Journal:  Am J Hypertens       Date:  2008-03-13       Impact factor: 2.689

7.  Metabolic syndrome and target organ damage in untreated essential hypertensives.

Authors:  Cesare Cuspidi; Stefano Meani; Veronica Fusi; Barbara Severgnini; Cristiana Valerio; Eleonora Catini; Gastone Leonetti; Fabio Magrini; Alberto Zanchetti
Journal:  J Hypertens       Date:  2004-10       Impact factor: 4.844

8.  Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay.

Authors:  Stein Hallan; Arne Asberg; Morten Lindberg; Harald Johnsen
Journal:  Am J Kidney Dis       Date:  2004-07       Impact factor: 8.860

Review 9.  Albuminuria: a target for treatment of type 2 diabetic nephropathy.

Authors:  Dick de Zeeuw
Journal:  Semin Nephrol       Date:  2007-03       Impact factor: 5.299

10.  The spectrum of left ventricular hypertrophy in a general population sample: the Framingham Study.

Authors:  D D Savage; R J Garrison; W B Kannel; D Levy; S J Anderson; J Stokes; M Feinleib; W P Castelli
Journal:  Circulation       Date:  1987-01       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.